Zurcher Kantonalbank (Zurich Cantonalbank) Adma Biologics, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$34.1 Billion
Q4 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 65,960 shares of ADMA stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,960

Previous 61,374 7.47%

Holding current value

$1.44 Million

Previous $1.23 Million 7.75%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$15.62 - $22.62 $71,633 - $103,735	4,586 Added 7.47%	65,960 $1.13 Million
Q3 2024 Nov 07, 2024	SELL	$11.21 - $20.03 $952 - $1,702	-85 Reduced 0.14%	61,374 $1.23 Million
Q2 2024 Jul 29, 2024	SELL	$5.98 - $11.18 $586 - $1,095	-98 Reduced 0.16%	61,459 $687,000
Q1 2024 Apr 25, 2024	BUY	$4.4 - $6.74 $21,344 - $32,695	4,851 Added 8.55%	61,557 $406,000
Q4 2023 Jan 30, 2024	BUY	$3.08 - $4.52 $30,082 - $44,146	9,767 Added 20.81%	56,706 $256,000
Q3 2023 Oct 25, 2023	BUY	$3.47 - $4.61 $60,169 - $79,937	17,340 Added 58.58%	46,939 $168,000
Q2 2023 Aug 07, 2023	SELL	$3.12 - $4.22 $4,087 - $5,528	-1,310 Reduced 4.24%	29,599 $109,000
Q1 2023 May 08, 2023	SELL	$3.01 - $3.87 $31,719 - $40,782	-10,538 Reduced 25.43%	30,909 $102,000
Q4 2022 Feb 01, 2023	BUY	$2.47 - $3.88 $51,193 - $80,416	20,726 Added 100.02%	41,447 $160,000
Q2 2022 Aug 09, 2022	SELL	$1.43 - $2.2 $1,803 - $2,774	-1,261 Reduced 5.74%	20,721 $41,000
Q1 2022 Apr 21, 2022	BUY	$1.28 - $1.83 $28,136 - $40,227	21,982 New	21,982 $40,000

Others Institutions Holding ADMA

# of Institutions

349

Shares Held

182M

Call Options Held

1.72M

Put Options Held

846K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $4.29B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Adma Biologics, Inc. Transaction History